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Abstract
Chronic infection with hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular 
carcinoma worldwide. Following the discovery of HCV 3 decades ago, the identification of the 
structure of the viral proteins, combined with high-throughput replicon models, enabled the 
discovery and development of direct-acting antivirals. These agents have revolutionized care of 
patients, with cure rates of more than 90%. We review the status of direct-acting antiviral therapies 
for HCV infection and discuss remaining challenges. We highlight licensed compounds, discuss 
the potential to shorten therapy even further, and review different options for treatment failure and 
resistance. We also provide an overview on clinical experience with generic agents and evidence 
for their efficacy. Finally, we discuss the need for new drugs and outline promising targets for 
future therapies.
Keywords
hepatitis C; direct acting antivirals; resistance; treatment failure
Corresponding authors: David R. Nelson MD, Department of Medicine, University of Florida, Gainesville, FL, USA, phone 
3523748700, nelsodr@ufl.edu., and Thomas F. Baumert, MD, Inserm U1110, Université de Strasbourg, 3 Rue Koeberlé, F-67000 
Strasbourg, France, phone: +33368853703, Thomas.Baumert@unistra.fr. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of interest TFB is a co-inventor on patent applications and a patent on Claudin-1 specific antibodies for treatment of chronic 
HCV infection filed by Inserm, the University of Strasbourg and Genovac. He has received grant support of Biotest and served as an 
advisor for Gilead and Biotest. JKL has received research grant support from AbbVie, Allergan, Conatus, Genfit, Gilead, and 
Intercept; and has served as consultant to Bristol-Myers Squibb and Gilead. DRN has received research grant support from AbbVie, 
BMS, Gilead Janssen, and Merck. He has is a stockholder of Target PharmaSolutions. TB has received research support from AbbVie, 
Roche, BMS, Gilead, Novartis, Merck/MSD, Intercept, Janssen, Novartis, Sequana Medical, and Pfizer; provided consultancy, 
speakers bureau and participated in advisory boards for AbbVie, Alexion, Bayer, Boehringer Ingelheim, BMS, Gilead, GSK, Intercept, 
Janssen, MSD/Merck, Merz, Novartis, Sequana Medical and Roche
HHS Public Access
Author manuscript
Gastroenterology. Author manuscript; available in PMC 2020 January 01.
Published in final edited form as:
Gastroenterology. 2019 January ; 156(2): 431–445. doi:10.1053/j.gastro.2018.10.024.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rapid advances in therapy with oral direct-acting antivirals (DAAs) have resulted in 
significant improvement in safety and efficacy—7 all-oral regimens have been approved by 
the Food and Drug Administration (FDA) for treatment of chronic hepatitis C virus (HCV) 
infection. These produce rates of sustained virologic response (SVR) that exceed 95% 1. 
DAAs target various points of the HCV replication cycle, binding directly to components of 
the replicase complex or initiating RNA chain termination. The rapid virologic response 
observed with potent DAA combinations have permitted progressively shorter durations of 
treatment with equivalent rates of SVR—although only patients without factors associated 
with lack of response, such as cirrhosis and prior treatment failure. Guidelines include 
regimens as short as 8 weeks for selected patients (Table 1), and registration trials and real-
world cohorts have confirmed the efficacy of these regimens. However, it would be 
beneficial to shorten treatment durations even further, to reduce cost for patients and payors, 
decrease adverse effects, and optimize treatment adherence.
Three pan-genotypic combination regimens (sofosbuvir and velpatasvir; sofosbuvir, 
velpatasvir, and voxilaprevir; and glecaprevir and gibrentasvir) are effective in treatment of 
all HCV genotypes, as well as patients with cirrhosis or HIV coinfection. These pan-
genotypic DAAs could simplify care and facilitate treatment expansion worldwide. We 
review key remaining challenges and opportunities in the treatment of chronic HCV 
infection, including further truncation of treatment duration with ultrashort regimens, 
incorporation of generic formulations of DAA regimens, roles and interpretations of testing 
for resistance-associated substitutions (RAS), evidence-based approaches to treatment of 
DAA failures, and the remaining need and prospect for future HCV therapies.
How short can therapy be?
Two oral DAA regimens have been approved for 8-week treatment duration in selected 
patients with chronic HCV infection, including sofosbuvir and ledipasvir and glecaprevir 
and pibrentasvir (G/P). The combination of sofosbuvir and ledipasvir can be used in patients 
infected with HCV genotype 1 who are treatment-naïve, without cirrhosis, non-black, and 
HIV-negative. In the phase 3 ION-3 protocol, 647 treatment-naïve patients without cirrhosis 
infected with HCV genotype 1 were randomly assigned to groups given 8 or 12 weeks of 
sofosbuvir and ledipasvir. No significant difference was observed between groups in 
proportions of patients with an SVR (93% vs 95%), although rates of virologic relapse were 
higher in the 8-week group 2. This finding was confirmed in several large real-world cohorts, 
which reported similar levels of efficacy for the 8- and 12-week regimens 3–5. In contrast to 
sofosbuvir and ledipasvir, the 8-week regimen of glecaprevir and pibrentasvir has been 
approved by the FDA for treatment-naïve, patients without cirrhosis infected with HCV 
genotypes 1–6. This recommendation is supported by the results of 4 clinical trials, 
including the ENDURANCE-1 protocol, in which 703 DAA-nai’ve patients without 
cirrhosis infected with HCV genotype 1 were randomly assigned to groups given 8 or 12 
weeks of glecaprevir and pibrentasvir. In this study, 99.1% (348/351) of patients in the 8-
week group and 99.7% (351/352) of patients in the 12-week group achieved an SVR (ref 6). 
In the ENDURANCE-3 protocol, 390 patients without cirrhosis infected with HCV 
genotype 3 who were naïve to DAA therapy were randomly assigned to receive 8 or 12 
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weeks of glecaprevir and pibrentasvir. In this study, 95% (149/157) of patients in the 8-week 
group and 95% (222/233) of patients in the 12-week group achieved SVRs. In the 
SURVEYOR-II, Part 4, and ENDURANCE-4 protocols, 266 DAA-naiïve patients without 
cirrhosis and infected with HCV genotypes 2, 4, 5, or 6 were given glecaprevir and 
pibrentasvir for 8 or 12 weeks. There were no significant differences in SVRs between 8- 
and 12-week groups of patients with HCV genotype 2 infection (98% vs 99.5%) or genotype 
4–6 infections (93% vs 99%) 7. Preliminary data from 2 real-world cohorts (from Italy and 
Germany) confirmed the efficacy of the 8-week regimen 8,9.
In summary, short (8-week) treatment with oral DAA regimens showed high levels of 
efficacy in clinical trial and real-world cohorts of patients infected with HCV genotypes 1–6. 
These are recommended as equivalent to 12-week regimens within AASLD/IDSA, EASL, 
and APASL guidance documents, but should not be used in patients with cirrhosis or prior 
exposure to DAA regimens. Whereas the 8-week regimen of sofosbuvir and ledipasvir has 
been approved by the FDA for select treatment-naïve patients without cirrhosis with HCV 
genotype 1 infection, the 8-week glecaprevir and pibrentasvir regimen has been approved for 
all treatment-naïve patients and those previously treated with interferon and ribavirin, 
without cirrhosis, infected with HCV genotypes 1, 2, 4, 5, or 6, and all treatment-naïve 
patients without cirrhosis with HCV genotype 3 infection. Short-course regimens under 12 
weeks are not recommended for other DAA regimens such as sofosbuvir and simeprevir; 
paritaprevir, ritonavir, and ombitasvir with dasabuvir; grazoprevir and elbasvir; sofosbuvir 
and velpatasvir; or sofosbuvir, velpatasvir, and voxilaprevir.
Ultrashort DAA regimens
Due to the efficacy of 8-week regimens, multiple ultrashort regimens, combining 3 or 4 
DAAs for treatment durations less than 8 weeks, have been studied. Despite early optimism 
from a trial by Kohli et al, which reported 95%–100% SVR in 60 treatment-naïve patients 
with HCV genotype 1 treated with sofosbuvir and ledipasvir or sofosbuvir and ledipasvir 
plus either GS-9669 or GS-945110, several subsequent trials have confirmed low rates of 
SVR with 4- and 6-week regimens11,12, particularly among individuals with advanced liver 
disease. Advanced liver disease is associated with lack of SVR, which may be related to 
factors such as altered immune signaling pathways and impaired drug delivery, uptake, and 
metabolism due to venous shunting, liver fibrosis, and impaired liver function 13. In the 
LEPTON protocol, Gane et al evaluated the efficacy of 4-, 6-, or 8-week regimens of a 3 
DAA combination of sofosbuvir, velpatasvir, and GS-9857 in 161 treatment-naïve or 
previously treated patients with HCV genotype 1 or 3 infections, with or without 
compensated cirrhosis. The 4-week regimen led to an SVR in 27% (4/15) of treatment-naïve 
patients with HCV genotype 1 infection without cirrhosis, whereas the 6-week regimen led 
to an SVR in 79% (62/78) of patients 14. The C-SWIFT trial was a singlecenter study of 
treatment-naïve patients without cirrhosis infected with HCV genotypes 1 or 3 given 
sofosbuvir, grazoprevir, and elbasvir for 4–12 weeks. SVRs were achieved by 32% (10/31) 
and 87% (26/30) of patients treated for 4 and 6 weeks, respectively 15. The FOURward 
study was an open-label trial of 28 treatment-naïve, patients without cirrhosis infected with 
HCV genotype 1 who received daclatasvir, asunaprevir, and beclubavir for 4 or 6 weeks. 
SVRs were achieved by 23% and 57% of patients treated for 4 and 6 weeks, respectively 16. 
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The low rates of SVR in patients receiving 4 or 6 weeks of treatment reveal the limitations 
of ultrashort regimens, despite the high potency 3- or 4-DAA combinations—particularly in 
patients with 1 or more factor associated with lack of SVR.
Industry benchmarks for SVR (>95%) are unlikely to be achieved with ultrashort regimens 
with 3 or 4 DAAs available in clinical practice—particularly in real-world settings, in which 
many patients have factors associated with lack of SVR. Approved regimens of 8–12 weeks 
are associated with excellent safety and efficacy, but ultrashort or response-guided regimens 
are not recommended 17-21.
How Effective Are Generic Agents?
The World Health Organization (WHO) released a global strategy on viral hepatitis which 
calls for the elimination of HCV infection as a public health threat by 2030, defined by an 
80% reduction in new HCV infections, and a 65% reduction in HCV-associated mortality 27, 
which is estimated to result in an absolute decrease in annual global HCV-associated deaths 
from 1.4 million to fewer than 0.5 million 28. However, this will require diagnosing 90% of 
people living with HCV and treating 80% of diagnosed people with DAAs. Despite major 
advances in therapy, ongoing deficits in the care cascade for chronic HCV persist 29,30, 
although small steps of progress are being achieved in screening and diagnosis 31, linkage to 
care 32, and treatment, most notably within the Veterans Health Administration 33.
However, in the US and worldwide, access to treatment is a main barrier to eliminating 
HCV, due to the high costs of drugs 34–36. Within high-income countries and upper middle-
income countries, drug costs remain prohibitively high; the nominal price of sofosbuvir for 
12 weeks across 26 Organization for Economic Cooperation and Development countries 
range from US $37,729 in Japan to $64,680 in the US, with a median of US $42,017 37. 
Within low- and middle-income countries (LMIC), which have an estimated 72% of the 
infected individuals worldwide, a combination of tiered pricing by originator companies, 
voluntary and compulsatory licenses to generic manufacturers, unlicensed manufacture of 
generic medications within countries lacking patent protection, and import of generic 
medications, have permitted significant expansion of treatment through lower cost 
medications 38. According to the March 2018 WHO Progress Report on Access to Hepatitis 
C Treatment 39, voluntary license agreements for manufacturing of generic DAAs have been 
signed by 2 originator companies. Gilead has licensed 3 of products (sofosbuvir, sofosbuvir 
and ledipasvir, and sofosbuvir and velpatasvir) to 11 generic manufacturers in India; as of 
August 2017, the agreement permitted sale and marketing of generic formulations to 105 
LMIC. Bristol-Myers Squibb signed a voluntary license for the generic manufacture of 
daclatasvir, which permits sale and marketing in 112 LMIC through sublicensing 
agreements with 10 generic companies. Bioequivalent pharmacokinetics for generic 
sofosbuvir and daclatasvir in comparison to originator versions have been established 40, and 
minimum manufacturing costs for 12-week courses of combination DAAs range from US 
$122 for sofosbuvir and daclatasvir to US $192 for sofosbuvir and ledipasvir 41. The range 
of publicly reported prices for a 28-day supply of generic DAA formulations range from US 
$7.50-$143 for daclatasvir, US $20-$728 for sofosbuvir, US $75-$364 for fixed-dose 
combination sofosbuvir and ledipasvir, US $450 for fixed-dose combination sofosbuvir and 
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daclatasvir, and US $125-$130 for the fixed-dose combination of sofosbuvir and velpatasvir. 
Even at these lower prices for generic DAAs, and the decreasing prices of originator and 
generic DAAs over time, cost remains a barrier to access in many LMIC.
Although the availability of generic DAA formulations at prices far below US market prices 
has transformed the capacity to expand HCV treatment in LMIC, there are concerns about 
the safety, reliability, and efficacy of the generic supply chain. Early data from real-world 
studies indicate that SVR rates achieved with generic DAAs are similar to those reported 
with originator drugs in clinical trials and real-world settings (Table 2). Multiple 
observational studies have reported rates of SVR in patients with genotypes 1–4 HCV 
ranging from 92% to 98% with generic sofosbuvir and ribavirin, sofosbuvir and ledipasvir, 
or sofosbuvir and DAC regimens from India 42, China 43, Iran 44, Egypt 45, and Argentina 
46
, in addition to high rates of SVR in patients with chronic kidney disease 47, post-renal 
transplant 48, and thalassemia 48. Only 1 observational study reported on the efficacy of 
generic sofosbuvir and velpatasvir in 228 individuals (69 coinfected with HCV and HIV and 
159 infected with only HCV) treated with sofosbuvir, with or without ribavirin, for 12 
weeks. In this population, 97.1% individuals with HCV and HIV coinfection and 98.1% of 
individuals with only HCV infection achieved SVRs49.
Several large international cohorts have evaluated the efficacy of generic DAAs in real-world 
clinical practice. Freeman et al reported the results from the REDEMPTION-1 study, which 
evaluated 448 patients infected with HCV genotypes 1–6 receiving treatment with a generic 
DAA (sofosbuvir and ribavirin, sofosbuvir and ledipasvir ± ribavirin, or sofosbuvir and 
daclatasvir ± ribavirin). In this group, 28% of patients had cirrhosis and 43% had prior 
treatment. SVRs were achieved by 91% (275/301) of patients with HCV genotype 1 
infection and 90% (403/448) of patients overall 50. Hill et al studied the efficacy of generic 
sofosbuvir /LDV ± ribavirin or sofosbuvir daclatasvir, with or without ribavirin, in 616 
patients with HCV genotype 1–6 infections who obtained their drugs through online buyers’ 
clubs in Australia, Southeast Asia, or Eastern Europe; of this group, 11% had cirrhosis. 
Overall, 99% of subjects had SVRs (247/250), with no significant differences among 
genotypes or treatment regimens 51. Omar et al reported preliminary results from patients 
treated with generic DAAs in a national HCV treatment program in Egypt. During the first 2 
months of the program 18,378 patients with HCV genotype 4 infection began treatment with 
generic sofosbuvir and daclatasvir ± ribavirin, and 95.1% of patients overall had an SVR; 
premature treatment discontinuation was reported for only 1.5% of patients 52. An estimated 
330,000 individuals were treated in this program from October 2014 through March 2016—
continued reports of safety and efficacy are anticipated 53.
Early findings from analyses of regional and international cohorts indicate the efficacy of 
generic formulations of DAAs, with rates of SVR similar to those reported from clinical 
trials and real-world cohorts. However, caution is needed in the interpretation of these 
studies, which have been limited by predominantly observational study designs without 
control groups (no randomized controlled trials), relative paucity of safety, adherence, and 
follow-up data, variable sourcing of generic DAAs, reporting of per-protocol without intent 
to treat rates of SVR, and selection bias could not be excluded. Importantly, researchers 
recognize concerns about counterfeit DAAs and the reliability of DAAs produced with or 
Baumert et al. Page 5
Gastroenterology. Author manuscript; available in PMC 2020 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
without licenses from originator companies, so these analyses were conducted almost 
exclusively in context of generic sourcing from licensed manufacturers. Further studies are 
needed to determine whether similar findings will be observed for a broader range of generic 
sources.
In light of significant heterogeneity in study population, treatment infrastructure, and 
sources of generic DAAs within existing datasets, the observed SVR >90% is remarkably 
high and provides reassurance that similar efficacy may be expected as with originator 
DAAs. Nevertheless, strengthening trust in the manufacturing supply chain is essential to 
permit selection of quality-assured generic DAA products, particularly for procurement 
within large national treatment programs. Although additional investigation is warranted to 
confirm the safety and efficacy of low-cost generic DAAs in larger representative cohorts, 
generic DAAs will help facilitate broad expansion of the mass treatment programs necessary 
to achieve the WHO’s ambitious goal of eliminating HCV infection by 2030.
Management of DAA failures
Treatment with DAAs leads to selection for drug-resistant HCV variants. HCV infection is a 
master among viruses at acquisition of resistance-associated substitutions (RAS), which 
arise in patients receiving suboptimal antiviral regimens. Risk of treatment failure is low in 
patients receiving 2 different classes of highly active DAAs 54,55. However, even if we 
assume a low rate of treatment failure (less than 2% in previously untreated patients with 
compensated liver disease who adhered to an optimal first-line regimen), the number of 
patients who will need retreatment becomes significant given the enormous number of 
patients treated globally for HCV 56. It is not known whether broader use of generic DAAs 
in low- and middle-income countries is associated with the increase in treatment failure, 
which could lead to a worldwide increase in DAA RAS. Thorough and optimized 
management of DAA failures is required to prevent HCV-associated disease progression in 
individuals as well as to prevent transmission and further spread, worldwide, of HCV with 
RAS—especially in high-risk populations 57. For example, the longterm persistence of a 
highly fit strain of HCV, with substitutions associated with resistance to sofosbuvir and that 
is difficult to treat, was recently described in a population of men who have sex with men 
and are coinfected with HIV and HCV. This observation raises concerns of an international 
spread of difficult to treat virus variants 58.
Association of Failed DAA Regimens With RAS
In most patients who fail DAA therapy, strains of HCV emerge with variants that mediate 
resistance to the drug the patient received. The risk for selection of RAS is higher among 
patients with virologic breakthrough compared to patients with relapse. In 2 large 
multicenter studies (1 from European collaborators and 1 from Italy), the prevalence of 
drug-specific RAS after DAA failure ranged from 66% to 77% after a relapse, and 86% to 
97% after nonresponse or on-treatment virologic breakthrough, depending on the DAA 
regimen used 59,60. The proportion of patients with RAS varied among HCV subtypes—it 
was higher in patients infected with HCV subtype 1a (85.7%) or genotype 3 (92.3%) 
compared to other genotypes (73.9%). These findings support previously reported HCV 
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subtype-specific differences in the baseline prevalence of DAA-specific RAS observed in 
treatment-naive patients 61.
Duration of DAA treatment also matters—most patients with treatment failure after 
longterm DAA administration relapse with RAS, whereas after short-term treatment, the 
wild-type virus usually reappears. In a review of data from all phase 2 and 3 trails of 
ledipasvir and sofosbuvir, the percentages of patients with NS5A RASs after failure of 
ledipasvir and sofosbuvir were 37.5%, 66.7%, 94.7% and 100% in patients treated for 6, 8, 
12, and 24 weeks, respectively 62. If patients failed by 12 weeks treatment with sofosbuvir 
plus an NS5A inhibitor do not carry a strain of HCV with DAA-specific RAS, the presence 
of a viral variant that is resistant to the NS5A inhibitor can be suspected. Certain HCV 
subtypes (such as 1l and 4r) contain naturally occurring polymorphisms that could contribute 
to primary resistance to NS5A inhibitors—especially against ledipasvir 67,68. Although these 
HCV subtypes are rare in Western countries, they seem to have a broader distribution in 
Central African countries 67. These findings indicate the importance of collection of HCV 
sequence data from well-defined large cohorts in low- and middle-income countries 69.
Analyses from the European HCV Resistance Study Group and the Italian network 
VIRONET-C, which evaluated 1094 patients failed by different DAA-based regimens 
(mostly daclatasvir or ledipasvir plus sofosbuvir, simeprevir plus sofosbuvir, or the 2D or 3D 
regimens), showed that a higher proportion of patients failed by an NS5A inhibitor-based 
regimen developed HCV RASs than patients failed by NS3/4 protease inhibitor-based 
regimens (91.9% vs 66.9%). This could be due to the shorter half-life of the NS3/4-RAS 
inhibitors compared to NS5B inhibitors. 60. Among patients failed by an NS5A inhibitor 
regimen, more than 20% and up to 66% carry HCV strains with 2 or more NS5A RAS 62. 
Development of multiclass resistance is the biggest challenge to second-line treatment—it 
was observed in 44% of 282 patients previously treated with 2 or more classes of DAAs 
(26.6% of patients had RAS to NS3 and NS5A inhibitors and 11.3% of patients had RAS to 
NS3, NS5A, and NS5B inhibitors) 60. In contrast, selection of the RAS S282T—the only 
substitution shown to confer to resistance to the NSB5 inhibitor sofosbuvir in cultured cells, 
is rarely found in patients failed by sofosbuvir-containing regimens (<4%). However, RAS 
S282T is more frequently found in HCV genotype 4 compared to types 1 or 3 59,63,64. The 
significance of other RASs in patients failed by sofosbuvir-based regimens, like the L159F 
and C316N RASs is unclear. These RAS seem to increase the half maximal effective 
concentration (EC50) of sofosbuvir in co-existence with the RAS S282T65,66.
Testing for Baseline RAS
A genotype (analysis of RAS) to phenotype (susceptibility to DAAs) personalized approach 
to treatment (selecting the optimal combination from the available 3 different DAA classes, 
based on baseline RAS) seems logical. So why don’t guidelines support baseline tests for 
resistance— especially when facing second-line treatments for patients failed by a previous 
all-oral DAA regimen? 1,70. The positive predictive value for treatment failure associated 
with certain preexisting baseline RAS is low 71. Although RAS are part of the equation if 
treatment fails, RAS are not the only determinant—other features of patients, such as stage 
of liver disease, genetic factors, immune response, and sex, as well as level of HCV 
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replication and HCV subtype, all affect response to treatment 59,60,72,73. Cirrhosis, previous 
treatment and emergence of RAS for NS5A inhibitors (or multiclass RAS), and infection 
with HCV genotypes 1a or 3 are associated with DAA failure 54.
The gap between HCV genotypic and susceptibility to DAA treatment might involve time to 
restoration of HCV-specific immune response with DAA-mediated decrease HCV 
replication 74,75. The baseline innate immune response contributes to the efficacy of DAA 
therapy. The innate immune response can prevent emergence and further selection of RAS 
76
. Part of the confusion about tests for RAS arise from variations in methods to detect RAS 
and assess levels of resistance (usually by measuring fold change in EC50). However, there 
is also confusion because different studies evaluate drug-specific or DAA class-specific 
RASs in different HCV genotypes or subtypes 77. There is consensus that a drug-specific 
RAS must present in at least 15% of the HCV population to reduce odds for an SVR. 
However, a systematic review revealed limitations in methods of HCV sequencing; these 
must be overcome for development, validation, and sharing of standardized methods for all 
genotypes and subtypes 78.
The clinical implications of testing for RAS to select second-line treatments, especially for 
patients failed by NS5A inhibitor-based treatment, are limited (see AASLD/ISDA and 
EASL guidelines; Table 3). Selection of antiviral regimen based on baseline analyses of 
RAS and identification of DAA combinations most likely to be effective has been shown to 
be possible in real-world cohorts, and result in rates of SVR of approximately 90% 79. 
Testing for RAS after DAA failure might be of value for patients with limited access to the 
single-tablet triple regimen (such as voxilaprevir, velpatasvir, and sofosbuvir) or in areas 
where only regimens that require optimization based on pre-treatment resistance testing are 
available 70. A systematic review of how the effects of RAS to first- and second-line 
treatments vary among DAAs and HCV genotypes and subtypes could help guide selection 
of DAA combinations for clinical practice. This area of study is complex, and we must 
better understand how levels of resistance conferred by specific substitutions vary among 
HCV subtypes and for different DAAs (see Table 4) 80.
Treatment of Patients Failed by DAAs
Second-line treatment strategies should involve combinations of DAAs that target different 
viral proteins and have non-overlapping resistance profiles. Sofosbuvir has become the 
backbone of most of the recommended regimens for patients failed by DAAs, due to its 
pangenotypic activity and a high barrier to development of resistant virus 81. This nucleoside 
NS5B inhibitor is effective in nearly all patients, regardless of treatment history, except for 
patients with HCV strains that acquire the sofosbuvir-specific RAS S282T 63,65.
Failure of first-generation protease inhibitors
Patients failed by first-generation protease inhibitors (such as boceprevir and telaprevir) or 
suboptimal regimens of sofosbuvir plus ribavirin ± peg-interferon can be effectively treated 
with the combination of an NS5A inhibitor and sofosbuvir. These combinations produce 
SVRs in 94%–100% of patients, depending on cirrhosis, treatment duration, and addition of 
ribavirin 82. However, neither the role of treatment duration nor ribavirin has been fully 
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explored—the addition of ribavirin and/or extension of treatment to 24 weeks might be 
required. Regimens containing second-generation PI and NS5A inhibitors with high barriers 
to resistance, such as glecaprevir and pibrentasvir, and to a lesser extent elbasvir and 
grazoprevir, are also options for these patients 83–85. The AASLD/IDSA recommendations 
for treating patients after DAA failure, depending on the regimen that failed, are summarized 
in Table 5.
Failure of regimens that do not contain NS5A inhibitors
A second-line regimen that contains an NS5A inhibitor plus sofosbuvir was tested in a phase 
3 study of patients failed by DAA regimens that did not contain an NS5A inhibitor; this 
study excluded patients who received a DAA with peginterferon-based therapy 86. For 
comparison, some patients received a triple combination regimen containing all DAA classes 
(voxilaprevir, velpatasvir, and sofosbuvir). The triple regimen led to SVRs in 98% of 
patients compared to 90% of patients who received the dual regimen. The higher rate of 
relapse observed after dual therapy (9% vs 1% for the triple regimen) was due to relapse in 
patients with cirrhosis or infected with HCV subtypes 1a or 3. Consequently, the approved 
triple regimen is recommended for patients with HCV type 1a or 3 infections failed by 
regimens without peg-interferon or an NS5A inhibitor (see Table 3).
Failure of regimens containing NS5A inhibitors
Management of patients after failure of a regimen that contains an NS5A inhibitor is a 
challenge, because NS5A inhibitors are part of all treatment regimens, and the RAS that 
arise in NS5A tend to persist and can increase replication fitness 87,88. However, 96% of 
patients retreated with all 3 classes of DAAs in a single tablet (voxilaprevir, velpatasvir, and 
sofosbuvir) achieve an SVR (100% of patients with subtype 1b infection, 96% of patients 
with subtype 1a infection, 95% of patients with type 3 infections, and 91% of patients with 
type 4 infections) 86. The triple therapy regimen has therefore become the treatment of 
choice for patients failed by regimens containing a NS5A inhibitor.
A 3-class regimen could be the ultimate treatment for patients failed by an NS5A inhibitor, 
with or without an NS3/4 inhibitor. The regimen is effective with non-approved triple 
combinations such as sofosbuvir, daclatasvir, simeprevir plus ribavirin or sofosbuvir with 
grazoprevir and elbasvir plus ribavirin. These regimens may be useful in regions in which 
triple therapy is not available 89–91. Moreover, preliminary data from a phase 3b study 
evaluating glecaprevir and pibrentasvir treatment of patients with HCV genotype 1 infection 
failed by an NS5A inhibitor and sofosbuvir (with or without ribavirin) indicated that 95% of 
patients maintained an SVR for 4 weeks after treatment. However, even the 3-class regimen 
can fail, and then there is a high risk of multiclass resistance. Pibrentasvir has the highest 
level of efficacy against RAS in NS5A, of all the available NS5A inhibitors, so the triple 
combination of sofosbuvir, glecaprevir, and pibrentasvir (with or without ribavirin) might 
become an interesting rescue approach for the remaining non-responders 92.
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Are New Drugs Needed?
Given the unprecedented revolution in treatment paradigm in the treatment of chronic HCV 
infection by the licensing of DAAs, are the licensed and next-generation DAAs sufficient to 
eradicate HCV? Or, will new drugs and new targets still be needed? Observational studies 
from the real world indicate that more than 90% of patients with chronic HCV infection are 
cured by DAA-based regimens. Nevertheless, several challenges remain 93. Probably the 
most important challenge is the limited access to DAA regimens in low-resource countries 
but also in special populations in high resource countries such as patients with limited health 
care coverage or drug abuse 94. Indeed overall access to DAA has been estimated to be less 
than 10% of the HCV-infected patients on a global level 95. Another challenge is limited 
screening of HCV infection. The absent access and screening for most patients translates 
into very limited effect on the global burden of HCV-associated diseases such as HCC 96. 
One reason for limited access are the high costs of FDA-approved DAAs. Furthermore, 
management of special populations, or difficult to treat patients, require adapted treatment 
regimens and DAA resistance or failure can occur in a small minority of patients.
An emerging challenge is the growing number of HCV infections associated with the opioid 
epidemic 97. Compliance and access to DAA is limited in patients who inject drugs and 
curing HCV infection does not prevent re-infection, so a protective vaccine is needed, to 
decrease HCV prevalence, particularly in this growing population. Another clinical 
challenge is the persistent risk of HCC in patients cured of HCV infection but with advanced 
fibrosis or comorbidities such as diabetes. Although the risk of de novo HCC is reduced 
after an SVR to therapy, HCC can develop even more than 10 years after HCV clearance 101. 
Meta-analyses have shown that there are no differences in HCC risk following DAA cure or 
interferon-based treatment regimens. Post-SVR HCC development and recurrence is more 
frequent in some groups of patients that have undergone HCC resection 101. Given the 
increasing incidence of HCC and the challenges to prevention and early detection, we need 
alternative or commentary strategies to reduce HCC risk after HCV clearance for patients 
with advanced fibrosis. Despite the unprecedented success of DAAs, new targets and 
compounds can still provide opportunities to improve patient care.
What are the Most Promising Targets?
In addition to developing DAAs, researchers are developing strategies to stimulate the anti-
HCV immune response. For example, therapeutic vaccines might be used to boost T-cell 
responses to the virus, or broadly neutralizing antiviral antibodies to prevent HCV infection 
of grafts. In clinical trials, therapeutic vaccines have had only limited success compared to 
DAAs—most likely due to their inability to restore functional T-cell responses in patients 
with chronic infection and virus immune evasion102. Broadly neutralizing monoclonal 
antibodies have been successful in preventing HCV infection—monoclonal antibodies 
against the HCV envelope glycoprotein E2 were shown to prevent liver graft infection, alone 
or in combination with DAAs 103,104. strategies to boost the anti-virus immune response 
might be used to reduce risk of HCV infection and provide useful information for the 
development of a preventive HCV vaccine.
Baumert et al. Page 10
Gastroenterology. Author manuscript; available in PMC 2020 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Other agents in development target human factors required for viral infection. Studies of 
models of HCV infection have increased our understanding of the virus life cycle, and led to 
discovery of compounds that target hepatocyte factors required for the HCV life cycle, 
called host-targeting agents (HTA) 105. Studies in cell culture, animal models, and clinical 
trials show that HTA have broad antiviral activity and a high genetic barrier to drug 
resistance, most likely due to the low rate of mutation in human cells105. HTAs have 
synergistic effects with DAAs and are efficient against DAA-resistant strains of HCV. 
Several HTAs have shown effects in animal models and are being evaluated in phase 2 and 3 
trials.
Host molecules have been identified that are important for all steps of the virus life cycle 
including cell entry, replication, assembly, and egress (Fig. 1). Factors required for HCV cell 
entry include scavenger receptor class B member 1 (SRBI), the tetraspanin CD81, and the 
tight-junction proteins claudin 1 and occludin 106. The small molecule ITX-5061 interferes 
with binding of HCV to SRBI and was the first HCV entry inhibitor investigated in clinical 
trials. Although ITX-5061 had limited efficacy in patients with chronic HCV infection, it 
significantly limited virus evolution and delayed infection in patients undergoing liver 
transplantation 107. The limited potency of the compound combined with virus escape may 
have been the reasons for incomplete protection.
Monoclonal antibodies can also inhibit virus entry, by blocking the extracellular domains of 
cell receptors. Monoclonal antibodies against HCV entry prevent HCV infection in animal 
models104. Mice with humanized livers given antibodies against claudin were cured of 
chronic HCV infection, so entry inhibitors might be used to treat patients with chronic HCV 
infection 108. Furthermore, several natural compounds that interfere with HCV entry of cells 
have been explored, 109 although their clinical positions are unclear. It is important to note 
that combinations of entry inhibitors and DAAs have synergistic antiviral effects110. Entry 
inhibitors are of particular interest for preventing HCV infection in patients undergoing liver 
transplantation, including those receiving HCV-infected organs. This is because prevention 
of infection provides advantages compared to post-transplant treatment, when virus-induced 
disease may already have been established 104,111. Clinical trials are required to determine 
whether entry inhibitors might be effective during organ transplantation, compared to or in 
combination with DAAs.
Cellular miRNA122 is required for HCV replication, and has been explored as antiviral 
target in clinical trials. The stability of HCV RNA and its replication require microRNA-122 
(MIR122)112. In cells, miravirsen/SPC3649, a MIR122 antisense locked nucleic acid, 
inhibits HCV replication. MIR122 binding sites are highly conserved among HCV 
genotypes, so miravirsen has pan-genotype antiviral effects 113. In a clinical trial, 
administration of miravirsen resulted in a prolonged dose-dependent reduction in HCV RNA 
without serious adverse effects 114115. A single dose of RG-101, a hepatocyte-targeted N-
acetylgalactosamine-conjugated oligonucleotide that antagonizes MIR122, produced a 
significant decrease in HCV RNA in patients with chronic infection with different 
genotypes. Virus rebound occurred after administration of each compound, likely due to 
substitutions in MIR122 binding sites 115116.
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Safety is an important issue to address for HTAs. Although short-term administration of 
MIR122 inhibitors appears to be safe, long-term studies are needed, since suppression of 
MIR122 has been associated with liver disease progression and HCC in animal models117. 
Intravenous administration of an antagomir could be an option for patients who cannot 
comply with an 8–12-week oral course of therapy. This strategy may also be useful in 
patients who only present sporadically to health care providers. Furthermore, it may provide 
an opportunity to shorten DAA regimens, if included in combination therapy.
Cyclophilins are cell proteins that interact with the NS5A and have been explored as 
therapeutic targets118. Although these agents had robust antiviral efficacy in clinical trials 
124,125
, safety limitations delayed or halted their development. Moreover, several other cell 
factors involved in HCV assembly and egress, trafficking, and lipid metabolism have been 
explored (see Figure 1)105. However, clinical proof of concept is pending or was 
characterized by either limited efficacy or adverse effects precluding further development. 
Finally, repurposing of FDA-approved drugs has been proposed as a low-cost approach for 
treatment of HCV infection. A well characterized example is the use of the antihistamine 
chlorcyclizine and related compounds for treatment of HCV infection127.
HTAs could complement DAAs in treatment of HCV infection 128. Entry inhibitors provide 
a complementary strategy for prevention of HCV infection in patients undergoing organ 
transplantation. Furthermore, HTAs that target virus replication could reduce resistance to 
DAAs and shorten therapy duration. Trials are needed to determine how HTAs might be 
used in combination with DAAs. One challenge is the general lack of funding for research 
and development of new treatments, including HTAs. Increased funds from the public or 
foundations might provide opportunities to address future unexpected unmet medical needs 
such as DAA multi-resistance or not yet discovered long-term safety issues.
Future Directions
Thirty years after the discovery of HCV, the development of DAAs revolutionized the care 
of patients with chronic infection. Licensed DAAs achieve cure more than 90% of patients 
in the real world. Combinations have reduced the duration of therapy, although there appears 
to be a minimum length of treatment, and truncated regimens are not optimal for all patient 
populations. Difficult to treat patients, such as those with advanced liver disease, renal 
failure, or HCV genotype 3 infection, might benefit from the next generation of DAAs. 
However, most infected individuals live in low resource countries, so DAAs have a limited 
impact on the global burden of liver cirrhosis and HCC. Furthermore, the opioid epidemic is 
increasing the incidence of HCV infection in high resource countries. Although effective 
strategies have been developed to address DAA resistance and treatment failure, efforts must 
be continued to prevent and treat multi-resistant strains. DAA therapy decreases the overall 
progression of liver disease, yet a significant increase in risk of HCC persists following cure 
of HCV infection in patients with advanced fibrosis and/or co-morbidities. Further research 
efforts are needed to address these challenges and complement the therapeutic arsenal of 
DAAs.
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Figure 1. Hepatocyte Targets and the HCV viral life cycle.
In a simplified model of the HCV cycle human hepatocytes, agents inhibit virus cell entry, 
replication, assembly, and release. HCV lipoviroparticles (LVPs) circulating in the blood 
bind to hepatocyte cell surface receptors such as heparan sulfate proteoglycans, low density 
lipoproteins (LDL), and SR-B1. HCV is transferred to the claudin 1 and CD81 co-receptor 
complex and occludin. Following clathrin-mediated endocytosis and uncoating, the positive 
strand virus RNA is translated into a single polyprotein that is processed into at least 10 
proteins, which are anchored in the endoplasmic reticulum. Virus replication occurs in 
membranes derived from the endoplasmic reticulum (ER), called the membranous web, and 
requires cyclophilins and MIR122. The assembly process is induced by core protein 
trafficking to lipid droplets (LD). Morphogenesis of the virus is associated with synthesis of 
ver low densty lipoproteins (VLDL). New virions are transported and maturated through the 
Golgi before being released as LVPs. Assembly and egress requires factors such as 
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apolipoproteins (APOB and APOE), diglyceride acyltransferase (DGAT), and microsomal 
triglyceride transfer protein (MTTP). Entry and replication inhibitors have been tested in 
clinical trials. (figure modified from ref 105.).
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